[Inhibition of adrenergic beta receptors by N,N'-bis-[3-(2'ethoxyphenoxy)-2-hydroxypropyl]-ethylenediamine (Falirytmin) as compared to propranolol].
D000319:Adrenergic beta-Antagonists; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002415:Cats; D005029:Ethylenediamines / Q000494:pharmacology*; D005260:Female; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D007583:Jejunum / Q000187:drug effects; D008168:Lung / Q000187:drug effects; D009119:Muscle Contraction / Q000187:drug effects; D011433:Propranolol / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D014599:Uterus / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D005029:Ethylenediamines; D011943:Receptors, Adrenergic, beta; D011433:Propranolol; D007545:Isoproterenol
Uber die Hemmung adrenerger beta-Rezeptoren durch N.N'Bis-[3-(2'-äthoxyphenoxy)-2-hydroxypropyl]-äthylendiamin (Falirytmin) im Vergleich mit Propranolol